Clinical trial
Pyrazoloacridine in Treating Women With Metastatic Breast Cancer
NCT00002585 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00002585 |
|---|---|
| Title | Pyrazoloacridine in Treating Women With Metastatic Breast Cancer |
| Official title | PHASE II CLINICAL EVALUATION OF PYRAZOLOACRIDINE IN PATIENTS WITH METASTATIC BREAST CANCER |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | pyrazoloacridine |
| Enrollment | 20 |
| Start date | Feb 1, 1994 |
| Primary completion | Oct 1, 1999 |
| Completion | Jan 1, 2001 |
| First posted | Aug 11, 2004 |
| Last update posted | Mar 12, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: